China PROTAC Corporate Landscape and Pipeline Overview (2026): From Technological Breakthroughs to Clinical Competition

By:DengYue International Business Division

PROTAC (Proteolysis Targeting Chimeras) has become one of the most closely watched directions in next-generation global drug discovery. Unlike traditional small-molecule drugs that function by inhibiting protein activity, the core logic of PROTAC is to directly induce degradation of target proteins through the ubiquitin–proteasome system within cells, enabling a “destruction-based therapeutic strategy.”

This not only represents an upgrade in mechanism of action, but also reflects a fundamental shift in drug development—from “whether a protein can be inhibited” to “whether a protein can be eliminated.”

In China, this field is rapidly taking shape: a number of biotech companies and pharmaceutical firms have already entered clinical stages, but overall the sector remains in an early validation window. For industry stakeholders, investors, and clinical researchers, the real challenge is not whether programs exist, but how to clearly understand the structural landscape and the differences in actual development progress.

1. Why Has PROTAC Become a New Focus in Drug Development?

Traditional small-molecule drugs rely on binding to targets and blocking their function, but this approach has inherent limitations:

Many key disease-related proteins—such as transcription factors, scaffold proteins, or proteins without well-defined binding pockets—have long been considered “undruggable.” In addition, even when inhibition is successful, resistance can emerge due to mutations.

The breakthrough of PROTAC lies in its shift away from inhibition toward an “event-driven mechanism,” which directly induces protein degradation. This creates several structural advantages:

On one hand, it expands druggable space beyond the reach of conventional therapeutics;

on the other hand, it operates via a catalytic mechanism, where a single molecule can participate in multiple rounds of protein degradation;

meanwhile, because target proteins are completely eliminated, it is theoretically more difficult for classical resistance mechanisms to develop.However, the technology is still in an early stage, and its major limitations remain clear:

large molecular size leading to challenges in druggability, unstable pharmacokinetics in vivo, and an incomplete clinical validation pathway.

2. China PROTAC Corporate Landscape: From Technological Exploration to Clinical Competition

From an industrial structure perspective, PROTAC development in China can be broadly divided into three categories: clinically leading companies, technology-driven innovators, and platform-oriented pharmaceutical companies.

1) Clinically Leading Segment: Entering the “Data Validation Stage”

Within this tier, the most closely watched companies are those already in clinical trials and beginning to generate preliminary data.

Among them, BeiGene’s BTK degrader BGB-16673 is considered one of the most advanced BTK PROTAC programs globally. It primarily targets B-cell malignancies and patients with resistance to BTK inhibitors. Early clinical data have shown promising objective response rates, making it a flagship asset in this field.

Meanwhile, Haisco Pharmaceutical continues to advance multiple PROTAC programs in BTK and hematologic malignancies, building a relatively systematic hematology-focused pipeline based on its internal R&D platform.

In solid tumors, Hinova Pharmaceuticals focuses on androgen receptor (AR)-related programs, exploring PROTAC applications in indications such as prostate cancer.

In addition, Kintor Pharmaceutical has adopted a more differentiated strategy by developing an AR degrader (GT20029) as a topical formulation, targeting androgenic alopecia and acne—an uncommon application pathway in the PROTAC field.

2) Technology-Driven Innovators: Targeting High-Difficulty Targets

Compared with clinically leading companies, this segment places greater emphasis on “target breakthrough capabilities.”

LeadingTac Bio is a representative example. Its pipeline covers not only IRAK4 (in the immunology/inflammation space) but also highly challenging oncology targets such as KRAS G12D.

In particular, KRAS PROTAC is considered one of the most difficult development areas. Its success or failure will directly influence the upper boundary of PROTAC applications in solid tumors.

Companies in this category are generally characterized by higher target difficulty and higher risk, but also significantly greater potential value if successful.

3) Large Pharmaceutical Companies and Platform-Based Strategies: Entry Through BD and Partnerships

Unlike biotech companies, large pharmaceutical firms tend to enter the PROTAC space through platforms or partnerships rather than focusing on single assets.

For example, Hengrui Medicine primarily adopts a hybrid strategy combining external collaborations with internal platforms, rather than concentrating on a single pipeline.

Betta Pharmaceuticals has entered the field through licensing-in collaborations with overseas PROTAC technology companies (e.g., C4 Therapeutics-related directions), enabling rapid entry into the space.

The key advantage of this category lies in resource integration capabilities rather than single-target technological breakthroughs.

3. Real Development Structure of China’s PROTAC Pipeline

Overall, China’s PROTAC pipeline shows a clear “concentration + divergence” structure:

Hematologic malignancies remain the most advanced area, particularly BTK degraders, which have already entered early clinical validation and begun accumulating patient-level data.

Solid tumor programs—despite a rich set of targets such as AR, ER, and KRAS—are generally constrained by pharmacokinetic and tissue penetration challenges, resulting in slower overall progress.

In the field of autoimmune diseases, new targets such as IRAK4 are emerging, but most remain in early exploratory stages without large-scale clinical data.

Overall, China’s PROTAC field is currently in a transition phase from early to mid-stage clinical validation.

4. Core Bottlenecks: Beyond Technical Challenges

At a surface level, the main challenge of PROTAC appears to be chemical complexity. However, deeper issues exist in three areas:

First, druggability constraints:

Large molecular size and structural complexity lead to unstable oral absorption and tissue distribution.Second, clinical trial design complexity:

Because the mechanism involves protein degradation, traditional evaluation systems for inhibitors are not fully applicable.Third, information opacity:

Many pipelines remain in early stages, with data scattered across conferences and announcements, making it difficult to form unified assessments.This is also why, despite high attention, PROTAC remains difficult to systematically interpret in practice.

5. Approaching Inflection Points in the Industry

Over the next 2–3 years, several key inflection points are expected in the PROTAC field:

If BTK PROTACs successfully enter pivotal clinical stages or achieve approval, it will validate the commercial viability of the entire degradation technology pathway.

If KRAS PROTACs achieve breakthroughs, it would further extend the “undruggable target” paradigm.

Meanwhile, expansion of the E3 ligase system will determine whether PROTAC evolves from a single modality into a platform-based drug discovery system.

6. Conclusion: China PROTAC Is Entering a True Competitive Phase

Overall, China’s PROTAC landscape has transitioned from “concept validation” to “clinical competition,” but remains far from mature commercialization.

The next stage of competition will no longer be about “who has PROTAC programs,” but rather:

who can successfully execute clinical development,

who can solve druggability challenges,

and who can achieve true commercial realization earliest.In this process, the demand for structured, high-density information continues to grow rapidly. For organizations requiring continuous tracking of global PROTAC and innovative drug pipelines, professional pharmaceutical intelligence and resource platforms such as Hong Kong Dengyuemed can provide more structured insights into industry dynamics and clinical progress, thereby reducing decision-making noise.